By Kelly Cloonan
Hims & Hers Health is offering lab testing, part of the telehealth platform's growing focus on preventive care.
The company expects the new offering to add to its user base as it draws customers looking to prevent future health issues, expanding beyond treatments it's become known for, including hair- and weight-loss and sexual health.
"You know, size of this market is, I think every single person in the country," Chief Executive Andrew Dudum said. He expects the offering to eventually represent a $1 billion business.
Under the offering, Hims & Hers customers will access testing at Quest Diagnostics' 1,000-plus sites around the country, then receive results and consult with providers on the platform for a personalized plan that could include prescriptions, supplements or nutrition guidance, Dudum said.
A blood draw that captures 50 biomarker tests costs $199 a year, while a plan with two blood draws and 120 biomarker tests is priced at $499. The tests cover areas like heart health, metabolism, hormones, inflammation and stress.
"It's a price point that I think the majority of the country can afford," Dudum said.
Companies that process lab tests for doctors, such as Quest, have been offering a greater range of tests directly to consumers in recent years to meet growing demand. Quest's comprehensive health profile costs $385 and analyzes more than 75 markers.
Dudum didn't disclose the financial terms of the deal, but said the scale of Hims & Hers's platform helps it negotiate with testing providers to offer lower prices. As of Sept. 30, the San Francisco company had 2.5 million subscribers.
A Quest spokesperson said the company's relationship with Hims & Hers strengthens its position as a preferred lab partner for consumer health companies. Quest has also announced lab testing partnerships with wearable technology company Whoop and smart ring maker Oura Health in recent months.
Hims & Hers expects to continue scaling its testing capabilities, and eventually lowering prices further, through negotiating with testing partners as well as acquisitions, investments in other companies or building its own testing infrastructure, Dudum said. The company recently contributed to a $325 million private placement in Grail, which sells a blood test for early cancer detection.
"The aim is both to build a foundation here that can bring the best of healthcare, truly, like the most advanced diagnostics and care onto the platform, and then simultaneously be working every quarter to bring the cost to the consumer down," Dudum said.
The company expects to eventually offer at-home testing devices, additional biomarker tests in areas like bone and brain health, and detection for chronic and life-threatening conditions, it said.
The move comes as patients take an increasingly active role in managing their health, in part due to a shortage of doctors and long wait times for appointments.
Dudum expects Hims & Hers's on-demand providers to fill that gap when it comes to lab testing.
"Educating you about what the next steps could be, is a void that I think I'm really, really excited to fill," he said, adding, "These metrics are confusing without it, and the next steps are unknown without that hand holding."
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
November 13, 2025 17:52 ET (22:52 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.